Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Objective: To clarify the effects of isoflavone intake on bone resorption and bone formation. Methods: We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed o...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of clinical nutrition Ročník 62; číslo 2; s. 155 - 161
Hlavní autoři:	Ma, D.F, Qin, L.Q, Wang, P.Y, Katoh, R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.02.2008 Nature Publishing Nature Publishing Group
Témata:	administration & dosage Alkaline phosphatase Amino Acids Amino Acids - urine Biological and medical sciences biomarkers blood serum Bone density bone formation Bone growth bone metabolism Bone resorption Bone Resorption - prevention & control bone specific alkaline phosphatase Care and treatment chemistry Citation analysis Clinical Nutrition Clinical trials Confidence intervals Deoxypyridinoline Diet Diseases of the osteoarticular system drug effects Epidemiology Feeding. Feeding behavior Female Food and nutrition Fundamental and applied biological sciences. Psychology Glycine max - chemistry Health aspects human nutrition Humans Internal Medicine Isoflavones Isoflavones - administration & dosage Isoflavones - pharmacology Markers Medical sciences Medicine Medicine & Public Health Menopause Meta-analysis Metabolic Diseases Middle Aged Nutrition Older people original-article Osteogenesis Osteogenesis - drug effects Osteogenesis - physiology Osteoporosis Osteoporosis, Postmenopausal Osteoporosis, Postmenopausal - prevention & control Osteoporosis. Osteomalacia. Paget disease pharmacology physiology Phytochemicals Postmenopausal women Prevention prevention & control Public Health randomized clinical trials Randomized Controlled Trials as Topic Soy products soybeans Treatment Outcome urine Vertebrates: anatomy and physiology, studies on body, several organs or systems Women China isoflavone bone metabolism bone-specific alkaline phosphatase deoxypyridinoline soy osteoporosis Alkaline phosphatase Diseases of the osteoarticular system Phosphoric monoester hydrolases Esterases Soybean Metaanalysis Osteoarticular system Osteoporosis Randomization Clinical trial Female Woman Consumption Human Isoflavone Nutrition Enzyme Resorption Metabolic diseases Metabolism Hydrolases Bone
ISSN:	0954-3007, 1476-5640
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Objective: To clarify the effects of isoflavone intake on bone resorption and bone formation. Methods: We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966-April 2006), the Cochrane Controlled Trials Register, EMBASE (1985-January 2006), Science Citation Index and PUBMED (updated till April 2006). Results: Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by -2.08 nmol/mmol (95% confidence interval (CI): -3.82 to -0.34 nmol/mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 microgram/l (95% CI: 0.22-2.75 microgram/l). Decreases in the urinary Dpyr concentration with isoflavone intake of <90 mg/day and with treatment lasting less than 12 weeks were -2.34 nmol/mmol (95% CI: -4.46 to -0.22 nmol/mmol) and -2.03 nmol/mmol (95% CI: -3.20 to -0.85 nmol/mmol), respectively. Conclusions: Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if <90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.
Bibliografie:	http://dx.doi.org/10.1038/sj.ejcn.1602748 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 content type line 23 ObjectType-Feature-1
ISSN:	0954-3007 1476-5640
DOI:	10.1038/sj.ejcn.1602748